首頁>>行業新聞

美國基因治療公司Cancer Genetics采用RNAscope技術發現淋巴瘤PD-L1表達及其免疫應答的精細模式

發布日期:2018-01-18 16:38:00

聽說了一個重大新聞:美國基因治療公司Cancer Genetics采用RNAscope技術發現淋巴瘤PD-L1表達及其免疫應答的精細模式,該研究發表於第59屆美國血液學會(ASH)年會。我們一起去看看吧!Cancer Genetics advances understanding of immune response andmeasurement in lymphomas by combining PD-L1 expression analysis with RNA analysis

· 該研究發表於第59屆美國血液學會(ASH)年會

· 該研究重點關注DLBCL(彌漫性大B細胞淋巴瘤)

· 該研究使用RNAscope技術獲得精準醫療信息

轉載自CGI公司網頁新聞報道:

· RUTHERFORD, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today

announced results of a study demonstrating the potential value of being platform-agnostic and choosing the best diagnostic modality to evaluate an important molecular biomarker, PD-L1, in DLBCL(Diffuse Large B-Cell Lymphomas). The results (abstract 1477) were presented on Sunday, December 10, 2017 at the 59th ASH Annual Meeting in Atlanta.

新澤西州盧瑟福市2017年12月11日電(全球通社) - Cancer Genetics 公司(納斯達克股票代碼:CGIX)--分子診斷技術和腫瘤精準醫療的領導者-今天宣布了一項研究結果。該研究展示了診斷平台研究的潛在價值,篩選出了評估彌漫性大B細胞淋巴瘤中重要分子生物標誌物PD-L1的最佳診斷方式。其研究結果(摘要1477)於2017年12月10日(星期日)發表於亞特蘭大第59屆ASH年會。

20180116170113793.png.jpg

· The study compared performance of multiple antibody clones against PD-L1 and the current standard diagnostic modality, immunohistochemistry (IHC), to an in-situ hybridization (ISH), usingRNAscope®1 approach to determine the expression of PD-L1 in diffuse large B-cell lymphoma (DLBCL) cells, a particularly aggressive form of lymphoma.

該研究采用RNAscope®1技術檢測彌散性大B細胞淋巴瘤(高度惡性淋巴瘤)中的PD-L1,對比了PD-L1多克隆抗體免疫組化(IHC)標準診斷技術和原位雜交(ISH)技術。

· Although the two modalities demonstrated relative concordance related to the identification of PD-L1 expression, there were differences that indicated that RNA-ISH may be the superior approach. First,RNA-ISH appeared to be more sensitive, identifying cases of PD-L1 expression that were negative using IHC. Second, high PD-L1 expression identified by RNA-ISH, but not IHC, was highly correlated withnon-germinal center B-cell subtype, gains at the PD-L1/9p24 locus (a predictor of PD-L1 inhibitor response) and demonstrated a trend toward worse overall survival. The study demonstrates that choiceand integration of diagnostic modalities can provide key additional information to assist oncologists to more accurately select therapeutic options for their patients.

研究發現,兩種方法的檢測結果呈現出相對一致性,但存在一些差異,而這些差異恰巧表明使用RNAscope的RNA-ISH技術可能更好:

· 首先,RNA-ISH更敏感,能檢測出IHC檢測陰性結果病例中的PD-L1。

· 其次,RNA-ISH檢測結果表明,PD-L1/9p24位點擴增和高表達的PD-L1(PD-L1抑製的預測因子)與非生發中心B細胞亞型以及整體生存率走低相關,而IHC檢測沒有體現該結果。

· 該研究表明,選擇和整合正確的診斷方式,可以獲得關鍵輔助信息,從而幫助腫瘤學家作出更加精準的治療方案。

· “Precision oncology is all about better identifying the biomarkers in a patient’s tumor that both assist in diagnosis and drive a treatment plan tailored to the patient’s cancer with the objective of obtaining an optimal clinical outcome,” said Panna Sharma, President and CEO of Cancer Genetics. “This means that companies and laboratories in precision oncology should utilize the platform or platforms that generate the best validated information to drive treatment. This study demonstrates for a particular tumor type, DLBCL, that RNA-ISH generates superior information compared to IHC alone, which has been the standard for many years. We at Cancer Genetics would like to take this approach further to the benefit of the oncology community and the patients they treat.”

Cancer Genetics總裁兼首席執行官Panna Sharma說:“精準腫瘤學的目標是更精準地檢測患者腫瘤細胞中的生物標誌物,幫助診斷並製定個性化腫瘤治療方案,以獲得最佳的臨床療效”。“這意味著精準腫瘤學公司和實驗室應該利用能夠提供最佳驗證信息的平台來推動治療。這項研究表明,對於特定的腫瘤類型,如DLBCL,RNA-ISH技術優於使用多年的標準技術IHC,可提供更多有效信息。Cancer Genetics希望進一步使用這種診斷方法,為腫瘤學界和腫瘤患者謀利。

  • 服務熱線:0991-6644346

  • 地址:新疆烏魯木齊市高新區北區西彩路181號生物醫藥園708室

Copyright © 2018-2019 www.di1miao.com 新疆大发888生物科技有限公司 All Rights Reserved.
網站技術支持: